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AbstrACt
Introduction Dengue is an important and well-
documented public health problem in the Asia-Pacific and 
Latin American regions. However, in Africa, information 
on disease burden is limited to case reports and reports 
of sporadic outbreaks, thus hindering the implementation 
of public health actions for disease control. To gather 
evidence on the undocumented burden of dengue in Africa, 
epidemiological studies with standardised methods were 
launched in three locations in Africa.
Methods and analysis In 2014–2017, the Dengue 
Vaccine Initiative initiated field studies at three sites in 
Ouagadougou, Burkina Faso; Lambaréné, Gabon and 
Mombasa, Kenya to obtain comparable incidence data 
on dengue and assess its burden through standardised 
hospital-based surveillance and community-based 
serological methods. Multidisciplinary measurements of 
the burden of dengue were obtained through field studies 
that included passive facility-based fever surveillance, 
cost-of-illness surveys, serological surveys and healthcare 
utilisation surveys. All three sites conducted case detection 
using standardised procedures with uniform laboratory 
assays to diagnose dengue. Healthcare utilisation surveys 
were conducted to adjust population denominators in 
incidence calculations for differing healthcare seeking 
patterns. The fever surveillance data will allow calculation 
of age-specific incidence rates and comparison of 
symptomatic presentation between patients with dengue 
and non-dengue using multivariable logistic regression. 
Serological surveys assessed changes in immune status 
of cohorts of approximately 3000 randomly selected 
residents at each site at 6-month intervals. The age-
stratified serosurvey data will allow calculation of 
seroprevalence and force of infection of dengue. Cost-of-
illness evaluations were conducted among patients with 
acute dengue by Rapid Diagnostic Test.
Ethics and dissemination By standardising methods 
to evaluate dengue burden across several sites in Africa, 
these studies will generate evidence for dengue burden 
in Africa and data will be disseminated as publication in 
peer-review journals in 2018.
bACkground  
Dengue fever, a mosquito-borne flavivirus 
infection caused by four related but antigen-
ically distinct dengue viruses (DENVs, sero-
types 1–4), is a major and rapidly increasing 
global public health problem. Recent studies 
have estimated an annual incidence of 
50–100 million symptomatic infections glob-
ally.1 Dengue is a high burden disease that 
disproportionately affects countries in the 
tropics and subtropics, many of which have 
limited healthcare resources.2 Although one 
dengue vaccine has been recently licensed 
in several endemic countries, the vaccine has 
restricted age and epidemiological indica-
tions. Other prevention and control measures 
such as vector control are suboptimal as 
strengths and limitations of this study
 ► There have not been population-based studies 
conducted with a multidisciplinary approach (ie, 
surveillance, healthcare utilisation and serosurvey 
in one catchment area population). Data from the 
passive surveillance will be used to calculate annual 
incidences of dengue and data from the serosurvey 
will estimate the force of infection and prevalence.
 ► The studies were conducted in three locations 
in Africa, based on standardised methods and 
laboratory algorithm. Thus, comparison by site 
would be possible.
 ► This is not a cohort study. The passive facility-based 
surveillance may lead to underestimation of the 
burden of dengue fever by measuring incidence 
based on only those that sought care at our study 
facilities.
 ► There may be limited generalisability of our study 
results to other dengue-endemic parts of Africa.
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stand-alone interventions,3 4 and no drugs for treatment 
are currently available.
Like in Asia and the Americas, epidemics of dengue 
were reported from Africa in the late 19th and early 20th 
centuries.5 6 Specifically for Africa, there are records of 
multiple dengue case reports between 1964 and 1968 with 
DENV 2 in Nigeria.7 Data from several studies conducted 
in the 1960–1970s in Nigeria supported a substantially 
high level of immunity in adults as well as children.8 9 
In 2011, Amarasinghe et al conducted a comprehensive 
review of literature on dengue in Africa and described 
that dengue cases have been reported in 34 countries 
in Africa, with most of these countries also having Aedes 
mosquitoes.6 However, prior studies which suggested 
the presence of dengue in Africa were limited by their 
retrospective design or sample collection (blood donors 
or sample collected from surveys of other diseases), and 
often from travellers, with a small number of reported 
autochthonous cases, to demonstrate the true, popula-
tion-based, burden of dengue. Also, while many dengue 
endemic countries in Asia and Latin America have 
mandatory reporting of dengue cases to public health 
authorities and national surveillance systems in place 
to monitor incidence patterns,10 most African countries 
lack such established reporting mechanisms and only 
sporadic outbreaks and individual case reports have been 
documented. In addition, the frequently non-specific 
clinical presentation of dengue may be difficult to distin-
guish from the myriad other infectious diseases present 
in Africa, since dengue diagnostic assays are not widely 
available. Thus, the burden of dengue remains largely 
unknown in Africa.6 11 Without such dengue burden data, 
informed decision-making about prevention and control 
measures, including dengue vaccine introduction, in 
Africa are not possible.
Limited by surveillance capacity hindering continuous 
reporting in the region, there had not been frequent and 
systematic reporting of dengue in Africa. African ancestry 
is known to be protective against severe dengue and the 
candidate genes were recently identified in a Cuban 
patient.12 13 Bhatt et al’s modelling of the global dengue 
burden suggests high burden in Africa in terms of equal 
numbers of infections (both apparent and inapparent) as 
in Latin America.1 There are new findings about dengue 
in Africa, but there is still much unknown about the magni-
tude of the dengue problem in the continent. To improve 
estimates of population-based dengue disease burden in 
Africa and validate whether the undocumented burden 
of dengue is as high in Africa as in the Americas with 
empirical data, the Dengue Vaccine Initiative (DVI) initi-
ated field studies at three sites in West (Ouagadougou, 
Burkina Faso), West-Central (Lambaréné, Gabon) and 
East Africa (Mombasa, Kenya). In each of the three sites, 
a standardised package of study components, including 
passive facility-based fever surveillance, healthcare utilisa-
tion surveys, cost-of-illness surveys and serological surveys 




Study sites were selected, in part, based on their likeli-
hood of supporting DENV transmission. To select sites, 
we considered dengue outbreaks and cases reports in 
the literature, available seroprevalence studies as well as 
country-specific dengue risk maps of the probability of 
DENV transmission and the level of evidence of dengue 
presence, reporting the uncertainty of the consensus 
estimates of dengue in Africa.7 14 In addition, adequate 
research infrastructure to implement the studies was 
taken into account. Finally, inclusion of different regions 
of Africa was also a factor in site selection. Thus, Ouaga-
dougou, Burkina Faso; Lambaréné, Gabon and Mombasa, 
Kenya were selected, respectively, to measure the burden 
of dengue in selected sites from West, (West-) Central and 
East Africa.
In Burkina Faso, the first reported dengue outbreak 
occurred in Ouagadougou in 1982 due to DENV-2.6 
Serological prevalence of dengue antibodies among 
pregnant women and blood donors was found to be 
26.3% in a rural setting (Nouna village) and 36.5% in an 
urban setting (Ouagadougou) in 2006.15 More recently, 
an observational study conducted by Ridde et al among 
febrile patients consulting at selected study facilities 
in 2013–2014 showed 8.7% (33/379) to be positive by 
dengue rapid diagnostic test (RDT) and 15 of 60 samples 
tested by RT-PCR to be dengue-positive.16 With evidence 
for the presence of dengue, along with a strong health 
and demographic surveillance system (Ouaga-HDSS) 
which could be used to describe the demographic charac-
teristics of the catchment area, a field study was initiated 
in Ouagadougou, Burkina Faso in December 2014.
In Gabon, cases of dengue haemorrhagic fever 
(DHF) caused by up to three different DENV serotypes 
have been reported, and dengue seroprevalence has 
been found to be between 5% and 20%.17–19 Results 
of a recently published study demonstrated sero-
prevalence of 12.3% among toddlers approximately 
30 months of age in semirural Lambaréné between 
2007 and 2010.20 However, a different study in 2005–
2008 suggested minimal DENV transmission in rural 
areas of Gabon.21 This latter study examined anti-
bodies against dengue in individuals from randomly 
selected villages representing about 10% of all Gabo-
nese villages. Blood samples were tested by anti-DENV 
IgG and IgM capture ELISA and found to have only 
minimal IgG (0.5%) and IgM (0.5%) seroprevalence. 
Based on these low prevalences, the authors concluded 
that there was no active circulation of DENV in rural 
Gabon. However, the low seroprevalence may have 
been affected by low sensitivities of the tests used, 
leading to a high rate of false negative results and/
or selection bias in the blood sample pool among the 
selected villagers.22 Seroprevalence estimates in the 
2007/2010 study may have also been impacted by the 
possibility of false-positive results due to IgG cross-re-
activity among flaviviruses.21 Nevertheless, given the 
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possibility of DENV circulation in Gabon, a field 
study was initiated in Lambaréné in March 2015 in 
a community with a catchment population of about 
77 000 residents, using the clinical research infra-
structure of the Centre de Recherches Medicales de 
Lambaréné (CERMEL), benefiting from experienced 
research staff who conducted a large Phase 3 malaria 
vaccine trial.23 24
In Kenya, more evidence is available for the pres-
ence of dengue based on local data. Dengue was the 
most common viral pathogen in retrospectively tested 
blood specimens from HIV-negative survey samples 
from the 2007 Kenya AIDS Indicator Survey. Anti-
body testing for dengue as well as chikungunya and 
Rift Valley fever was performed by IgG ELISA using 
either commercial kits or CDC assays; 12.5% were 
found to be dengue-positive.25 Similarly, a household 
survey found 13% of individuals from 701 households 
in Mombasa had serological evidence of either past 
or current DENV infection.26 These data suggest 
that there is more dengue in Kenya than indicated 
by public health reporting, possibly due to misdi-
agnosis.25 26 A field study was initiated in Mombasa, 
Kenya in March 2016.
study participants
For the passive facility-based fever surveillance, individ-
uals who met the following criteria were eligible for study 
enrolment:
1. Age 1–55 years old.
2. Resident of the catchment area covered by healthcare 
facilities participating in the study, without plans to 
move out of the catchment area within 12 months.
3. Signed informed consent and assent for those aged 
between 7 (13 for Kenya) and 17 years.
4. Patients presenting with current fever (axillary tem-
perature ≥37.5°C) or history of fever for ≤7 days 
duration without localising signs (fever caused by a lo-
calised infection as well as fever with a known and con-
firmed aetiology other than dengue, such as malaria 
Figure 1 Description of the study components, including passive facility-based fever surveillance, healthcare utilisation 
surveys, cost-of-illness surveys and serological surveys. There are two arms in the study package, composed of four parts. In 
the health facility-based arm of the study package, there are passive facility-based fever surveillance and cost-of-illness survey 
embedded within the surveillance. In the community arm of the study, there are serological survey and healthcare utilisation 
survey.
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confirmed by malaria RDT, as listed in the patient 
identification standard operating procedure [SOP]).
For the serological survey, criteria 1–3 were applied. 
For the healthcare utilisation survey, household inter-
views were conducted among the heads or representatives 
of the household invited from each family participating 
in the serosurvey.
study area and population
Burkina Faso, located in West Africa, has a population of 
14 017 462. The country is mainly rural with about 29% 
of the population reported to be living in urban areas in 
2014. However, Burkina Faso is urbanising rapidly and is 
positioned as the country with the fourth fastest urbani-
sation in the last 25 years.27 28 The capital, Ouagadougou, 
has a population of 2 741 128. The majority of the popu-
lation live in urban settings. About 45% of the popula-
tion are under 15 years of age.29 The city is divided into 
12 districts and 52 sectors. Ouagadougou is the country’s 
largest city and the cultural and economic centre. The 
city is part of the Soudano-Sahelian area, with a rainfall 
of about 800 mm per year. The rainy season is from May 
to October, with a mean temperature of 28°C (82°F). 
The cold season runs from December to January, with a 
minimum average temperature of 16°C (61°F). During 
the hot season, which runs from March to May, the 
temperature can reach as high as 43°C (109°F).
The HDSS is in place in Ouagadougou. Ouaga-HDSS 
monitors a population of 81 717 residents; according 
to this surveillance system, the city population is very 
stable with a rate of migration of 4.1% and more than 
80% of the inhabitants with ownership of their houses 
[20]. A map of the city and the study area is shown in 
figure 2.
Gabon, located on the west coast of Central Africa, has 
an area of nearly 270 000 square kilometres (100 000 sq. 
mi) with a population estimated at 1.5 million. Its capital 
and largest city is Libreville. In 2014, it is reported that 
87% of the Gabonese population lived in urban areas.28 
The sixth largest city, Lambaréné, the capital of Moyen-
Ogooué province, is located 75 km south of the equator, 
with a population of 25 257 in 2009. The majority of 
Lambaréné residents live in semirural areas. About 42% 
of the Gabonese population is under 15 years of age.29 
Similarly, Lambaréné’s population is relatively young with 
about 50% under 20 years of age.
The health services of Gabon are mostly public, but 
there are some private institutions as well. With one of 
the best medical infrastructure in the region, almost 
90% of the population have access to healthcare services. 
Albert Schweitzer Hospital (ASH) is a private institution 
which served as a study site for the passive fever surveil-
lance study.30 31 The study area in Lambaréné is shown in 
figure 3.
Figure 2 Map of the study area in Ouagadougou, Burkina Faso.
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Kenya, located in East Africa, lies on the equator, 
covering 581 309 km2 (224 445 sq. mi), with a popula-
tion of approximately 45 million people in 2014.32 Kenya 
generally has a warm and humid tropical climate but is 
diverse, ranging from the cooler climate around the 
capital city, Nairobi, to a hot and dry climate inland as 
well as a desert-like climate in the north-eastern regions 
along the border with Somalia and Ethiopia.32 The 
capital, Nairobi, is a regional commercial hub. The main 
industries include agriculture, exporting tea and coffee 
as well as the service industry.
Kenya is divided into 47 semiautonomous counties. 
Mombasa is the country’s second largest city after Nairobi 
and is located on the east coast of the country.32 Admin-
istratively, Mombasa is the capital of Mombasa County, 
which was formerly called Coast Province. This overall 
Coast region covers over 80 000 km2 in the south-eastern 
part of Kenya, constituting about 15% of the country's 
land area, with a population of 3 325 307 residents.
The main economic driver of Mombasa is tourism 
and trading industry. Mombasa itself has a population 
of about 1.3 million with almost 50% of the population 
under 15 years of age.29 Increasingly, the population of 
the province lives in urban areas; at present about 45% 
live in Mombasa and other urban centres. The ‘long 
rains’ period begins around April and the ‘short rains’ 
period begins in October.32 Mean annual temperature 
ranges from 24°C to 27°C, but maximum temperature 
averages over 30°C between January and April.
Figure 4 shows the area of Mvita subcounty of Mombasa, 
which was the catchment area for the study in Kenya, with 
a catchment population of 74 735 residents. The map 
indicates the three facilities involved in the study.
sample size
Given the paucity of available age-specific dengue inci-
dence data in the study countries or nearby countries, it 
was difficult to obtain population-based incidence to make 
assumptions when calculating sample sizes. The required 
catchment population for the passive facility-based fever 
surveillance was roughly estimated based on the limited 
data available in the literature. Annual incidence esti-
mates were calculated based on available prevalence esti-
mates with the assumption that the outcome of interest 
has zero prevalence at age zero, and that force of infec-
tion is constant. It was assumed that prevalence estimates 
found for one particular age group would be adjusted as 
the annual incidence and used across all ages.
Wichmann et al calculated an expansion factor for 
children by comparing data from three cohort studies 
to national surveillance data in Southeast Asia.33 For 
children in Thailand, the age-specific expansion factors 
Figure 3 Map of the study area in Lambaréné, Gabon.
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calculated were 11.85 for <5 years, 8.76 for 5–9 years 
and 7.81 for 10–14 years.33 The results show that, even 
for Asia where better reporting and surveillance systems 
are available, there is a considerable degree of under-re-
porting. For Africa, there may be more dengue cases 
under-ascertained (not seeking care) and under-reported 
(not reported even if a patient with dengue seeks care, 
given that dengue is not one of the routinely notifiable 
diseases in Africa), but such information on the extent 
of underestimation of dengue was not available.34 35 Also, 
the incidence estimates used in our sample size calcula-
tions were not from population-based studies. While it 
would have been ideal to adjust the incidence further 
for likely underestimation, the annual incidence used 
in sample size calculations could not be adjusted for 
possible under-reporting due to the lack of data. The 
sample sizes were calculated with 95% confidence levels 
and a margin of error at a fixed significance level within 
25% of the true proportion of incidence. This gives rela-
tive precision of 75%, considering the gap in evidence 
for dengue incidence in the study areas. The final sample 
sizes were calculated by assuming 10%–20% (variable by 
site) non-response rate or loss to follow-up. The required 
catchment population size for the fever surveillance study 
in Burkina Faso was estimated to be 100 000, Gabon to be 
77 000 and Kenya to be 70 000. In these catchment popu-
lations, the number of enrolled subjects depends on the 
number of eligible patients who seek care at the study 
facilities. How many eligible febrile episodes would actu-
ally present at our study facilities was difficult to predict; 
but after assessment of the volume of febrile patients at 
the facilities, a realistic upper limit for enrolment for a 
study period of approximately 1.5 years was set at 3000 
subjects to offer enrolment to all consenting eligible 
patients.
For the serological survey, the sample size was calcu-
lated similarly using the prevalence proportion based 
on published literature. Seroprevalence of 0.304 for 
Burkina Faso,15 0.123 for Gabon,21 and 0.144 for Kenya36 
were used. With the same confidence levels and allowed 
margin of error and assuming 10%–30% (variable by site) 
non-response rate, the sample size was calculated to be 
3000 participants at each site. Again, with the scarcity of 
data from the selected countries, there were no other 
Figure 4 Map of the study area in Mombasa, Kenya.
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prevalence estimates reported or estimates from different 
age groups. As prevalence is expected to increase with age 
and higher prevalence would give a smaller sample size, 
our calculations are likely to be conservative.
study components
Fever surveillance—design and methods
To determine burden due to symptomatic dengue in 
each of the three sites in Burkina Faso, Gabon and 
Kenya, passive facility-based fever surveillance was imple-
mented in a well-defined catchment area population. 
In Burkina Faso, the surveillance study was initiated 
in December 2014 in five selected primary healthcare 
centres, locally called ‘Centre de Santé et de Promotion 
Sociale’, in the municipality of Ouagadougou, with a 
catchment population of 105 000 residents. This project 
was implemented in collaboration with Centre Muraz in 
Bobo-Dioulasso, EQUITE sante programme (a collabo-
rative programme between University of Montreal and 
Action-Gouvernance-Integration-Reinforcement, AGIR, 
based in Ouagadougou, funded by the Canadian Insti-
tute of Health Research) and DVI. In Gabon, the surveil-
lance study was initiated in the ASH serving a catchment 
population of 130 000 residents in the Moyen-Ogooué 
and surroundings within Lambaréné, in collaboration 
with CERMEL and Institute of Tropical Medicine in 
Tubingen, Germany. In Kenya, the surveillance study was 
implemented at Ganjoni dispensary, Tudor subcounty 
Hospital and Coast Provincial General Hospital, serving a 
catchment population of 70 000 residents in Mombasa, in 
collaboration with Kenya Medical Research Institute and 
Ministry of Health of Kenya.
As described in figure 5, both outpatients and inpa-
tients at the designated study facilities, who meet inclu-
sion criteria as mentioned earlier were tested for dengue, 
first with SD Dengue Duo RDT. Dengue confirmation 
was done by detection of dengue virus in serum samples 
using PCR as well as antidengue IgM and IgG antibodies 
in acute and convalescent serum by ELISA (SD Dengue 
IgM & IgG capture ELISA tests, Standard Diagnostics, 
Yongin-Si, Korea).10 37 Every consecutive patient meeting 
inclusion criteria was eligible for enrolment during the 
study period. Infants<1 year old were not included due 
to operational limitations, such as difficulty of infantile 
bleeding.
In Ouagadougou, Burkina Faso, the fever surveillance 
was initiated in December 2014 and continued until 
February 2017 (approximately 2 years). In Lambaréné, 
Gabon, the fever surveillance was initiated in April 
2015 and continued until January 2017 (approximately 
1.5 years). In Mombasa, Kenya, the fever surveillance 
was initiated in March 2016 and continued until May 
2017 (15 months).
Among subjects enrolled in the fever surveillance, 
those who were positive by dengue rapid diagnostic test 
were offered further enrolment in the cost-of-illness 
survey, consisting of interviews on the day of acute illness 
visit, day 10–14 from the first visit and day 28, if illness 
continues. The cost-of-illness survey questionnaire was 
designed to estimate the direct medical, direct non-med-
ical and indirect costs associated with dengue-positive 
patients identified at study facilities. This survey also 
estimates the cost of treating dengue at the facility level. 
Data were gathered by linking patients’ medical records 
concerning outpatient visits, inpatient visits and service 
consumption (eg, diagnostic tests, medication and other 
services provided to patients). The cost-of-illness portion 
of the study will be described separately.
Fever surveillance—laboratory testing
As shown in figure 6, in all three sites, acute samples 
were tested using a commercial RDT for dengue NS1 and 
IgM/IgG (Dengue Duo, Standard Diagnostics, Yongin-Si, 
Korea). Dengue Duo RDT was used on the day of acute 
illness visit at the site of patient presentation (day 1). The 
acute and convalescent samples were subsequently tested 
at a local laboratory using dengue IgM/IgG ELISA (SD 
Dengue IgM & IgG Capture ELISA, Standard Diagnostics, 
Yongin-Si, Korea). The serum was separated and stored in 
4 aliquots of about 500 µL for various laboratory tests, as 
indicated in consent documents.
After ELISA testing, samples were shipped to the 
International Vaccine Institute (IVI) in Korea. Samples 
with positive results by RDT or ELISA, as well as a small 
number of samples with negative results, undergo further 
testing by RT-PCR at the Clinical Immunology Labo-
ratory of IVI. Four DENV serotype-specific real-time 
RT-PCR assays are used for laboratory confirmation of 
dengue and serotyping.38 The DENV 1–4 RT-PCR assays 
are carried out in 25 µL reaction mixtures containing 
5 µL template RNA, TagMan Fast Virus 1-step mastermix 
(Applied Biosystems), 0.9 µM of each primer and 0.2 µM 
probe.38 Amplification and detection are performed in a 
StepOne Plus real-time PCR system, and the baseline and 
threshold are determined using the auto-baseline and 
threshold feature in StepOne Software V.2.2.2 (Applied 
Biosystems). Thermocycling parameters are as follows: 
reverse transcription at 50°C for 5 min, inactivation at 
95°C for 20 s, followed by 45 cycles of fluorescence detec-
tion at 95°C for 3 s and annealing at 60°C for 30 s.38 A 
specimen is considered positive if target amplification is 
recorded within 40 cycles.
Serological survey—design and methods
While the facility-based fever surveillance studies provide 
estimates of the burden of medically attended dengue 
disease, evaluation of all DENV infections in a popu-
lation—including subclinical and mildly symptomatic 
infections, which impact immune status—is needed 
to capture the overall impact of dengue. As part of the 
study package, population-based serological surveys 
were conducted in the same catchment population 
used for the fever surveillance. At each of the three sites 
in Africa, the serosurvey was conducted on a cohort of 
approximately 3000 randomly selected residents of urban 
and semiurban parts of Ouagadougou, Lambaréné and 
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Mombasa. Without individual-level census information 
on all residents of Lambaréné and Mombasa, with help 
of community/village health workers, randomisation 
was done based on neighbourhoods (or defined areas 
for which the health workers/volunteers are respon-
sible) as cluster units. As the community/village health 
workers are familiar with the villages and their residents, 
they are good entry points into the communities. With 
these health workers, the field team screened houses in 
the selected villages by knocking on doors of every 5–7 
houses, depending on the household density per neigh-
bourhood. Also, demographic information collected in 
previous research projects conducted in the same area 
was used as a guide, if available. In the case of the site 
in Ouagadougou, HDSS data were available and the 
EQUITE SANTE, a CIHR funded research programme of 
the University of Montreal, had set up a geographic infor-
mation system database of houses in the study area. Using 
these data, households of potential enrolees of the sero-
survey were preselected randomly and household visits 
were made in Ouagadougou. In the three sites, about 45% 
of the serosurvey samples were targeted to be collected 
from children 1 to 14 years of age, and 55% were targeted 
to be collected from adults between 15 and 55 years of 
Figure 5 Patient flow in the fever surveillance. Eligible febrile patients identified and enrolled as study subjects followed these 
steps to complete participation in the passive fever surveillance. * A small number of those samples that are negative on ELISA 
or NS1 are tested with PCR to exclude false negative results of the ELISA. CRF, case report form. 
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age to reflect the age distribution of the general popula-
tion of the area. Household-based enrolment was offered 
to the head of the household until the specific cap for the 
age-group was reached in Lambaréné and Mombasa.
Randomly selected subjects 1–55 years of age under-
went phlebotomy (5 mL for children and 7 mL for adults) 
twice—before the rainy season and after the rainy season, 
at approximately 6-month intervals. The sera were eval-
uated using IgG indirect ELISA at baseline and after 
6 months. The presence of dengue IgG antibodies at 
6-month intervals will be used to estimate the level of 
occurrence of inapparent DENV infection and to calcu-
late the rate of infection in the catchment population. 
Flow cytometry-based DENV neutralisation assays will be 
applied to a subset of samples to assess for presence of 
dengue neutralising antibodies and seroconversion over 
the 6-month interval. In addition to overall seroconver-
sion, age-specific seroconversion estimates in the catch-
ment population as well as the proportion of inapparent 
infections will be determined.
Serological survey—laboratory testing
From the samples collected in the serosurvey, about 
200 µL of serum were used and tested at a local labora-
tory using dengue IgG ELISA (Panbio Dengue IgG Indi-
rect ELISA, Alere North America, Florida, USA). After 
ELISA testing for dengue IgG at the local laboratories, 
samples were shipped to IVI. Given potential serological 
cross-reactivity among flaviviruses,39 flow cytometry-based 
neutralisation assays will be performed against selected 
flaviviruses to include yellow fever virus, West Nile virus, 
Zika virus and Japanese Encephalitis virus, in addition 
to DENV 1-4, at the Clinical Immunology Lab of IVI.40 41 
About 50 samples per bleed for four bleeds in Burkina 
Faso and two bleeds in Gabon and Kenya will be tested.
About 1000 µL of serum is allotted for this proce-
dure. The flow cytometry-based neutralisation assays 
are performed in duplicate in 96-well cell culture plates 
with flat-bottom wells, each containing DC-SIGN-ex-
pressing U937 cells.40 The amount of virus used in the 
assay infects between 7% and 15% of the cells. Human 
immune sera are serially diluted and the virus is prein-
cubated with the sera for 1 hour at 37°C.40 The cells are 
washed, the virus and serum mixture is added to the cells 
for 1 hour at 37°C and the cells are further incubated 
for 24–48 hours at 37°C in 5% CO2. The cells are fixed, 
permeabilised and stained with fluoresce-conjugated 
monoclonal antibody 4G2, which recognises the flavivirus 
E protein.42 FACScan flow cytometer (Becton Dickinson, 
San Diego, California, USA) is used to analyse the cells.40 
The serum dilution that neutralises 50% of the viruses is 
calculated by nonlinear, dose-response regression analysis 
with Prism 4.0 software (GraphPad Software, San Diego, 
California, USA).
In addition, a Luminex-based multiplex immunoassay 
will be performed on a randomly selected subsample 
to assess for IgG to different flaviviruses.43 About 200 
samples per bleed for four bleeds in Burkina Faso and 
two bleeds in Gabon will be tested. Detection of IgG 
against ZIKV and each of the four DENV serotypes will be 
performed on patient serum samples using an in-house 
microsphere-based multiplex immunoassay (arbo-MIA) 
at the Clinical Immunology Lab of IVI.44 45 The arbo-MIA 
is based on a mixture of microspheres covalently coupled 
with either DENV-1, DENV-2, DENV-3, DENV-4 or ZIKV 
Figure 6 Laboratory testing algorithm for dengue. Samples from subjects of the passive fever surveillance would follow these 
steps of the testing algorithm for confirmation of dengue. *Dengue Duo®test is performed on enrolled febrile patients to identify 
dengue cases for immediate follow-up of dengue-confirmed cases in the cost-of-illness survey. **Selected samples, including 
those that were found positive by IgM and NS1 on Dengue Duo®,as well as those positive by IgM and IgG capture ELISA, will 
be tested with RT-PCR. 
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recombinant antigens (E protein domain III) produced 
in Drosophila S2 expression system. Briefly, microsphere 
mixtures were sequentially incubated in the dark under 
constant shaking with a 1:400 dilution of patient serum 
samples, with 2 µg/mL antihuman IgG biotin-conjugated 
antibody (Jackson Immunoresearch, West Grove, Penn-
sylvania, USA) and with 2 µg/mL streptavidin-R-phyco-
erythrin conjugate (Life technologies). After the final 
incubation, the median fluorescence intensity (MFI) 
of each microsphere set is quantified using a BioPlex 
200 instrument (Bio-Rad Laboratories, Hercules, Cali-
fornia, USA). Samples are considered seropositive if the 
ratio of MFI values obtained for the viral antigen to the 
control antigen is superior to the defined cut-off. The 
cut-off of the MIA is determined for each viral antigen by 
receiving operating characteristic (ROC) curve analysis 
using well-characterised sera.
In Lambaréné, the enrolment bleed took place in 
November–December 2015, while the second blood 
collection occurred in May 2016. In Ouagadougou, 
the enrolment bleed took place in May–June 2015 with 
follow-up blood collections in December 2015, June 2016 
and January 2017. In Mombasa, the enrolment bleed 
took place in May 2016 with the second blood collection 
in November 2016–February 2017.
Healthcare utilisation survey
As the passive fever surveillance was conducted at study 
facilities, patients with potential dengue could be missed 
if they seek care elsewhere. To identify the proportion of 
fever and dengue cases potentially missed by the passive 
surveillance system due to patients living in the study 
area but seeking care outside of study facilities, a popu-
lation-based healthcare utilisation survey was conducted 
in 400 randomly selected households from the study 
catchment area to characterise the healthcare utilisation 
patterns of the households when they have (self-reported) 
febrile episodes among the family members. In addition 
to assessing health-seeking behaviours of the residents, 
preferences in terms of health-seeking behaviour and 
respective reasons for their preferences were investi-
gated. The questionnaire was administered to 400 heads 
of households. Among 3000 residents who participated 
in the serosurvey, there were about 600 households. 
From these households, 400 heads of households were 
randomly selected and offered enrolment in the health 
utilisation survey. Heads of households or a senior repre-
sentative within the household were asked questions on 
health seeking patterns of their family members.
study questionnaires
For the fever surveillance study, questionnaires were 
administered at the acute illness visit and the convalescent 
visit. The convalescent visit may take place at the health-
care facility (10–14 days later) or at the patient’s home 
(15–21 days after the acute visit), according to patient 
preference and availability. The questionnaires were 
completed by medical staff of the study facilities, including 
demographic and clinical information (eg, signs, symp-
toms, past medical history, treatments prescribed and 
diagnoses). The same staff also completed the follow-up 
questionnaire at the convalescent visit within 21 days 
from the acute visit. Study nurses completed surveillance 
enrolment log. Lab technicians completed the lab section 
(mostly dengue-related diagnostics) and the forms were 
compiled by the study coordinator on site.
For the serosurvey component, questionnaires were 
administered at the household by trained field team staff 
at each serosurvey visit. Study nurses completed the ques-
tionnaire after a brief physical and medical examination. 
At the follow-up visit(s) in about 6 months, the same staff 
made the household visits to complete the follow-up ques-
tionnaire. Enrolment log was maintained by the study 
coordinator on site.
Variables of the surveillance questionnaires
The variables collected are listed in table 1.
Planned statistical analysis
From the fever surveillance data, incidence of symptom-
atic dengue among patients that seek healthcare at the 
study facilities will be calculated. Age-specific incidence 
rates in all the children and adults will be determined by 
referring to the size and distribution of the general popu-
lation of the study area at the time of surveillance as the 
denominator in calculation of the incidence of symptom-
atic dengue cases. Each person residing in the study area 
is assumed to contribute 12 months of person time to the 
denominator. Although the study areas all report a low 
migration rate, the in-migration is assumed to balance the 
out-migration of the population during the study period. 
Age-specific incidence of symptomatic dengue will be 
calculated by using age-specific denominators and the 
number of symptomatic dengue cases in eligible individ-
uals as the numerator.
Using the data collected in the Healthcare Utilisation 
Survey, the proportion of febrile cases missed by the 
passive surveillance system will be determined. Then 
using the proportion, the numerator will be further 
adjusted in recognition of those missed fever cases from 
the study area, which could have been dengue. Also, 
comparison will be made between those that agreed to 
participate and those that declined participation among 
the eligible potential enrolees. The enrolment log, which 
records basic information obtained during the screening 
process of potential enrolees, will be reviewed. In addi-
tion to checking that our sample of febrile cases is repre-
sentative of febrile patients of the general population 
in the catchment area, refusal rates will be determined 
based on information in the log. Then, the refusal rates 
will be used to adjust the numerator.
SPSS software will be used for analysis of the fever surveil-
lance data. Multivariable logistic regression will be used to 
compare confirmed patients with dengue versus patients 
with non-dengue febrile in terms of symptomatic presen-
tation, based on signs and symptoms collected from all 
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patients with laboratory-confirmed dengue by serology and 
RT-PCR, adjusting for possible confounders, such as age, 
days since onset of fever, primary versus secondary infection, 
inpatient versus outpatient and so on. Differences in symp-
tomatic complex of dengue fever (DF) (and DHF, if data 
allows) by age and serotype will be also determined using 
multivariable logistic regression.
As outpatient disease accounts for the greater part of 
dengue disease burden, clinical profile of individuals with 
DENV infection will be characterised by the type of treat-
ment (hospitalised vs outpatients) as well as by severity 
of the disease (severe vs non-severe by the 2009 WHO 
criteria).46 Classification is determined after the course 
of illness is completed (typically during the convalescent 
visit). Symptomatic dengue is classified as outpatient or 
hospitalised. Progression of dengue is recorded as DF, 
DHF I, DHF II, DHF III or DHF IV, and clinical patterns 
will be compared by the severity grade.46 47 These will be 
compared with results obtained from other DVI studies in 
Latin America (Colombia) and Asia (Thailand, Vietnam 
and Cambodia). Overall, comparisons will be made across 
Burkina Faso, Gabon and Kenya.
Table 1 List of variables collected in the passive fever surveillance data collection form
Topic Description Items
Basic information Demographic and basic information about the 
patient and the treatment received
Type of treatment, where patient is enrolled (IPD vs OPD)
Date of fever onset, duration of fever
Current temperature
Tourniquet test results
Patient’s address (district and village-level)




Current condition of the patient (self-report) and 
underlying diseases of the patient





A set of signs and symptoms that may be 
related to fever and dengue (dengue fever and 
dengue haemorrhagic fever) at both visits 1 and 
2
Rash, fatigue, headache, retro-orbital pain, neck/ear pain, 
sore throat, breathing difficulty, cough, expectoration, 
gastrointestinal signs (nausea/vomiting, diarrhoea, 
abdominal pain and so on), haemorrhagic signs (nose/
gum bleeding, ecchymosis, petechiae and so on), signs 
of shock (cyanosis, capillary refill), arthralgia, myalgia, 
loss of appetite, jaundice and so on
Medical history Previous dengue-related or other flavivirus 
infection as well as vaccination history (self-
report)
Previous dengue infection and related hospitalisation
Previous infection to other commonly circulating arboviral 
infection in the area (ie, Yellow fever vaccination history)
Laboratory 
findings
Records from the routine laboratory tests 
widely used in clinical fever/dengue patient 
management, as part of the hospital care 
procedure
Platelet count, haematocrit, haemoglobin, leucocytes, 
neutrophils, protein level, AST, ALT, urine test results and 
so on
Clinical diagnosis Clinician’s diagnosis with or without referring to 
the RDT
Diagnosis given by the physician based on clinical 
presentation after physical examination of the patient
Dengue testing 
results
Results from the dengue tests, mainly RDTs for 
dengue as well as other commonly circulating 
arbovirus in the area
Dates of blood draw
Test results of the RDT
IgM/IgG capture ELISA results
PCR results (if available)
Treatment Medicine(s) prescribed and the starting and end 
dates
Antibiotics, paracetamol, ibuprofen, aspirin and others 
that may be site-specifically prescribed
Outcome Outcome of this particular visit Hospitalised, returned home or referral
Hospitalisation Information collected only among hospitalised 
patients in the surveillance to record other 
severe signs and progression of illness
Admission and discharge diagnoses
Presence of haemorrhagic signs or shock syndrome
Hospital charges Expenses and hospital charges incurred by 
patient on the visit 1
Amount of the out of pocket payment by the patient or 
the family/or guardian
Breakdown of the hospital charges (laboratory, 
medication, admission-related charges)
Final outcome Outcome of the patient’s illness at the second 
visit
Final diagnosis given for the patient, outcome of illness
Completion of study participation (early termination and 
the reason and so on)
ALT, Alanine AminoTransferase; AST, Aspartate aminotransferase; IPD, Inpatient department; OPD, Outpatient department; RDT, Rapid 
Diagnostic Test. 
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With the age-stratified sera that reflect the age distribu-
tion of the general population of the country, the serolog-
ical survey sampling strategy ensures sufficient subjects to 
obtain precise age-specific estimates of seropositivity and 
seroconversion of the catchment area population. The 
seroconversion rate and change in the immune status will 
be determined by age group during the study period. The 
age-stratified serosurvey data will also allow calculation of 
the force of infection of dengue in the study population. 
After enrolment, there are subjects who drop out in the 
follow-up bleeds about 6 months later. Basic demographic 
information will be compared between those that completed 
participation and those with incomplete participation to 
check whether study subjects represent the catchment area 
population. Comparisons will be made among Burkina Faso, 
Gabon and Kenya.
Ethical considerations
To minimise inconvenience of the study to patients, clini-
cians and nurses were sensitised and trained regarding 
the study requirements and procedures in order for data 
collection to be integrated into routine patient care. The 
clinicians and nurses selected for the study receive coordi-
nated support from study field staff throughout the study 
process. Written informed consent and assent for partic-
ipants 7 (13 for Kenya)−17 years of age were obtained 
from patients by study staff. Study staff go through 
consent and assent documents for short summary of the 
disease, detailed description of study procedures and 
information on reimbursement. Patient data are docu-
mented in the study designated office; only the study staff 
have access to the data that are de-identified. Data are 
exclusively handled in the study office and stored safely in 
a protected database in the study office as well as on the 
DVI main server.
dIsCussIon
Dengue cases have been detected since the 1960s in 
Africa, and there has been continued presence of Aedes 
vectors in the continent.5 7 However, very few dengue 
studies have been conducted in Africa, and little evidence 
is based on population-based studies.6 Compared with the 
volume of evidence from SE Asia and the Americas, there 
is critical data scarcity on dengue in Africa. Suspicion of 
substantial dengue burden in Africa is based on limited 
reports of outbreaks and a handful of seroprevalence 
studies testing different viruses among samples that likely 
do not represent the general population. In the three 
countries selected for our field studies, somewhat more 
data are available, but are still very limited. In Burkina 
Faso, a recent observational study conducted in 2013 
reported that 8.7% of the febrile patients showed positive 
results on dengue RDT.16 In Gabon, one study suggested 
minimal DENV circulation in rural areas,21 while another 
study reported 12.3% seroprevalence, by IgG antibodies 
against dengue, among toddlers 30 months of age in 
semirural parts of Lambaréné.20 In Kenya, about 13% of 
the individuals in Mombasa have been reported to have 
evidence of past or current DENV infection by RT-PCR 
and IgM antidengue ELISA after the 2013 outbreak.26 
Despite the limited scope and generalisability of these 
studies, they suggest that there may be more dengue 
than previously appreciated due to underestimation and 
misdiagnosis.25 26
These studies suggest the presence of dengue and 
some level of underlying seroprevalence in the coun-
tries of our field studies. However, often these studies are 
limited by their retrospective design or sample collection 
(blood donors or sample collected from surveys of other 
diseases) to demonstrate the true, population-based, 
burden of dengue. We proposed to address this gap by 
population-based dengue surveillance and seropreva-
lence studies in West, (West-) Central and East Africa.
The present studies at three sites in Africa will provide 
important information on undocumented DENV circu-
lation in Africa. Such data will help to strengthen the 
evidence base for dengue burden in Africa. Better 
defined disease burden data based on our studies could 
be used to assess the relative need for dengue prevention 
and control measures, such as whether a dengue vaccine 
would be a cost-effective public health intervention for 
countries in Africa. Clinical findings from our studies 
could also be used as a guide for dengue case detection 
and case management.
The studies have some important limitations. We recog-
nise variability of dengue epidemiology over time and 
by region. Due to resource constraints, our studies are 
limited in terms of time frames and geographical extent. 
These constraints may limit the generalisability of our 
study results.
One potential source of bias in estimating the incidence 
of symptomatic dengue is under-ascertainment due to 
the community residents with relevant symptoms seeking 
care from other healthcare providers and facilities than 
the study facilities. As the study design remains passive 
surveillance, cases are ascertained only at our study facil-
ities. By estimating the proportion of febrile patients 
seeking care elsewhere as well as refusal rates among 
the potential enrolees that were screened for eligibility 
criteria, the degree of febrile patients missed by the study 
can be determined. Inverse probability weighting will be 
used to account for these potential subjects missed by 
the surveillance as adjustments in incidence calculation. 
Also, depending on the transmission volume of dengue 
or other cocirculating diseases with onset of fever, there 
may be patients that are diagnosed with other diseases 
and ruled out for dengue. Furthermore, with respect to 
dengue diagnostics for our serological surveys, there are 
other circulating flaviviruses in Africa leading to chal-
lenges in identifying antibodies to past dengue infec-
tions. While our testing plan assesses for some flaviviruses, 
others known to circulate in Africa, such as Banzi and 
Usutu viruses, are not part of the testing plan.48–50 Due to 
resource limitations, serological testing will be limited to 
yellow fever virus, West Nile virus, Zika virus and Japanese 
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Encephalitis virus as well as DENV 1–4. Therefore, in 
some cases, it may be difficult to determine prior expo-
sure to DENV versus other flaviviruses based on serolog-
ical data. This cross-reactivity may lead to overestimation 
of dengue force of infection.
In addition, the serosurvey and healthcare utilisation 
survey are conducted on a randomised subsample of the 
catchment area population and there may be limited 
generalisability of the data collected from these surveys. 
With unknown differences among those that agree to 
participate and those that do not agree, the data may not 
be representative of the general population of the study 
countries.
ConClusIon
The data collected from our studies will contribute to 
the assessment of the unknown dengue disease burden 
in Burkina Faso, Gabon and Kenya. These data can fill a 
gap in undocumented burden of dengue in the region 
and, collectively, may be used to infer dengue burden in 
other areas of Western, Central and Eastern Africa. Coun-
tries in Africa may not consider introduction of a dengue 
vaccine as a priority in the near future due to many other 
competing public health problems and limited resources. 
For cost-effective implementation of public health inter-
ventions, accurate data on dengue burden from epide-
miological studies would be needed for policy makers to 
make evidence-based decisions on control and prevention 
of dengue. Our studies will provide some much needed 
information based on population-based research to assess 
dengue burden in Africa.
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